Copied to clipboard!

Circulating cell-free DNA methylation profiling for detection, distinction, and estrogen receptor status classification of advanced breast cancer

We developed cell-free DNA (cfDNA) methylation signatures for minimally invasive breast cancer detection, distinction, and estrogen receptor (ER) status classification with cell-free Methylated DNA Immunoprecipitation and Sequencing (cfMeDIP-seq). We profiled peripheral blood plasma from 87 patients with mBC spanning ER-positive/HER2-negative (ER+/HER2-), HER2-positive, and triple-negative breast cancer (TNBC).

Type: Epigenetics
Archive: European Genome-phenome Archive (EGA)

1 Dataset 2 Publications

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000002405	This dataset contains raw paired-end FASTQ files generated from cfMeDIP-seq profiling of plasma cell-free DNA from patients with metastatic breast cancer spanning ER-positive/HER2-negative, HER2-positive, and triple-negative breast cancer subtypes (n=87).	Illumina NovaSeq 6000	87

Publications	Citations
Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer. Main SC, Elliott MJ, Singhawansa A, Zou J, Zeng Y, Cheng N, Yu C, Hilton JF, Awadalla P, He HH, Bedard PL, Lupien M, Bratman SV, Cescon DW. Cancer Res 86: 2026 4365-4380	0
Gene Expression Clustering of Lung Adenocarcinoma Tumors as a Prognosis Tool to Infer Progression-Free Survival. Renaut S, Saavedra Armero V, Boudreau DK, Gaudreault N, Abolfathi H, Maranda-Robitaille M, Lamaze FC, Biardel S, Gagné A, Desmeules P, Joubert P, Bossé Y. JTO Clin Res Rep 7: 2026 101008	0